Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: James Clarke who wrote (3234)	2/15/1998 12:35:00 AM
From: jeffbas	Read Replies (2) \| Respond to of 78602

Trying to justify valuation for Merck by saying how much lower its P/E would be if you capitalized R&D is, in my opinion, just as questionable as capitalizing the huge ad expenditures for a consumer products franchise like Coke to justify its P/E. Both are essential expenditures to the respective companies survival. The former creates hidden value on the balance sheet in terms of research in progress or value of patents and the latter brand value. Furthermore, if these expenditures were constant (which they are probably not) restating their historical records to capitalize them would increase assets but have no effect on current earnings - because the depreciation charges related to all past years' capitalized expenses would just equal this year's current expense.